Arnaud, Marion http://orcid.org/0000-0003-0534-2379
Chiffelle, Johanna http://orcid.org/0000-0002-8312-2681
Genolet, Raphael
Navarro Rodrigo, Blanca
Perez, Marta A. S. http://orcid.org/0000-0002-3963-5965
Huber, Florian
Magnin, Morgane http://orcid.org/0000-0002-9808-8973
Nguyen-Ngoc, Tu http://orcid.org/0000-0001-7574-2947
Guillaume, Philippe
Baumgaertner, Petra
Chong, Chloe
Stevenson, Brian J.
Gfeller, David http://orcid.org/0000-0002-3952-0930
Irving, Melita http://orcid.org/0000-0002-6849-7194
Speiser, Daniel E. http://orcid.org/0000-0003-2031-3250
Schmidt, Julien
Zoete, Vincent http://orcid.org/0000-0002-2336-6537
Kandalaft, Lana E. http://orcid.org/0000-0002-1575-6674
Bassani-Sternberg, Michal http://orcid.org/0000-0002-1934-954X
Bobisse, Sara
Coukos, George http://orcid.org/0000-0001-8813-7367
Harari, Alexandre http://orcid.org/0000-0002-1055-2090
Funding for this research was provided by:
Ludwig Institute for Cancer Research
Biltema Foundation Cancera Mats Paulssons
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_182384)
Article History
Received: 19 January 2021
Accepted: 20 August 2021
First Online: 15 November 2021
Competing interests
: G.C. has received grants from Celgene, Boehringer-Ingelheim, Roche, Bristol Myers Squibb, Iovance Therapeutics and Kite Pharma. The institution G.C. is affiliated with has received fees for G.C.’s participation on advisory boards or for presentation at a company-sponsored symposium from Genentech, Roche, Bristol Myers Squibb, AstraZeneca, NextCure, Geneos Tx and Sanofi/Avensis. The Centre Hospitalier Universitaire Vaudois (CHUV) and the Ludwig Institute for Cancer Research have filed for patent protection on the technology related to T cell expansion. S.B., A.H. and G.C. are named as inventors on this patent. M.A., M.B.S., S.B., G.C. and A.H. are named as inventors on a provisional patent application relating to subject matter disclosed herein filed by the CHUV and the Ludwig Institute for Cancer Research. The University of Lausanne and the Ludwig Institute for Cancer Research have filed for patent protection on the TCR sequencing technology. R.G. is named as inventor on this patent. G.C. has patents in the domain of antibodies and vaccines targeting the tumor vasculature as well as technologies related to T cell engineering for T cell therapy. G.C. holds patents around antibodies and receives royalties from the University of Pennsylvania regarding technology licensed to Novartis. V.Z. is a consultant for Cellestia Biotech. The remaining authors declare no competing interests.